Cadence Pharma launches Ofirmev in US

Cadence Pharma received the US Food and Drug Administration (FDA) approval for Ofirmev in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

In the trial, Ofirmev showed pain relief, reduced the consumption of opioids, and improved patient satisfaction.

Ofirmev is now available to hospitals across the US.

Cadence Pharma president and CEO Ted Schroeder said with the launch of Ofirmev, physicians will have access to the first new class of IV pain medication in nearly two decades.

"Our focus now turns to working closely with hospitals and physicians to expand access and utilization and establish Ofirmev as a foundational therapy in the management of pain in hospitalized patients," Schroeder said.